<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04655742</url>
  </required_header>
  <id_info>
    <org_study_id>valve-2014-04</org_study_id>
    <nct_id>NCT04655742</nct_id>
  </id_info>
  <brief_title>VitaFlow™ Transcatheter Aortic Valve System Pre-market Trial</brief_title>
  <official_title>A Prospective, Multi-center, Single-arm Clinical Investigation for Evaluation of the Safety and Effectiveness of the MicroPort™ CardioFlow VitaFlow™ Transcatheter Aortic Valve System in the Treatment of Severe Aortic Stenosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai MicroPort CardioFlow Medtech Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai MicroPort CardioFlow Medtech Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a pre-market clinical investigation aiming to evaluate the safety and effectiveness&#xD;
      of MicroPort™ CardioFlow VitaFlow™ Transcatheter Aortic Valve System for the treatment of&#xD;
      severe aortic stenosis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, multi-center, single-arm clinical investigation for evaluation of the&#xD;
      safety and effectiveness of the MicroPort™ CardioFlow VitaFlow™ Transcatheter Aortic Valve&#xD;
      System in the Treatment of Severe Aortic Stenosis. The investigation has two phases.&#xD;
&#xD;
      Phase I（FIM）：The FIM stage is a prospective, multicenter, single-arm observational clinical&#xD;
      investigation, aiming to evaluate the feasibility and safety of the MicroPort™ CardioFlow&#xD;
      VitaFlow™ Transcatheter Aortic Valve System. A total of 10 patients will be enrolled and&#xD;
      30-day clinical outcomes will be collected.&#xD;
&#xD;
      Phase II (Pivotal)：The pivotal stage is a prospective, multi-center, single-arm clinical&#xD;
      investigation with the performance goal, aiming to evaluate the safety and effectiveness of&#xD;
      MicroPort™ CardioFlow VitaFlow™ Transcatheter Aortic Valve System for the treatment of severe&#xD;
      aortic stenosis. A total of 110 patients will be enrolled in 11 clinical centers across&#xD;
      China. Clinical or telephone follow-up is scheduled at 30 days, 6 months, 12 months, and 2 to&#xD;
      5 years annually post-procedure.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 27, 2014</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Actual">September 6, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of device success-Phase I</measure>
    <time_frame>at immediate post-procedure</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>All-cause mortality at 12 months post implantation-Phase II</measure>
    <time_frame>at 12 months post-procedure</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of major adverse events -Phase I</measure>
    <time_frame>at 30 days post implantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemodynamic performance-Phase II</measure>
    <time_frame>at immediate post-procedure, discharge, 30 days, 6 months, 1 year and annually up to 5 years post implantation</time_frame>
    <description>Hemodynamic performance, including the mean prosthetic valve gradient(in mmHg), the Effective orifice(in cm^2), and the degree of prosthetic valve regurgitation measured by transthoracic echocardiography (TTE)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart function(NYHA)-Phase II</measure>
    <time_frame>at immediate post-procedure, discharge, 30 days, 6 months, 1 year and annually up to 5 years post implantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of safety events according to VARC2-Phase II</measure>
    <time_frame>at immediate, 30 days, 1 year and annually up to 5 years post implantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of major cardiovascular and cerebrovascular events(MACCE)-Phase II</measure>
    <time_frame>at immediate, 30 days, 1 year and annually up to 5 years post implantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of balloon pre-dilatation success-Phase II</measure>
    <time_frame>at immediate post implantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of balloon post-dilatation success-Phase II</measure>
    <time_frame>at immediate post implantation</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Aortic Valve Stenosis</condition>
  <arm_group>
    <arm_group_label>single arm, treatment group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects in the treatment group will be implanted with the VitaFlow™ Transcatheter Aortic Valve System</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>VitaFlow™ Transcatheter Aortic Valve System</intervention_name>
    <description>VitaFlow™ Transcatheter Aortic Valve System contains a valve stent-VitaFlow™ Aortic Valve, a delivery system-VitaFlow™ Delivery System,loading tools, a balloon dilatation catheter, and an introducer set</description>
    <arm_group_label>single arm, treatment group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria :&#xD;
&#xD;
        Enrollment was limited to patients who met all of the following criteria:&#xD;
&#xD;
          1. Age ≥ 70 years old(Phase II)/Age ≥18 years old,male or female who are not pregnant&#xD;
             (Phase I);&#xD;
&#xD;
          2. Patients have severe aortic stenosis: Mean gradient&gt; 40mmHg(1mmHg = 0.133kPa), or peak&#xD;
             velocity&gt; 4m/s, or an aortic valve area(AVA) &lt;1.0 cm² (or AVA index &lt;0.6 cm²/m²);&#xD;
&#xD;
          3. NYHA classification ≥ II;&#xD;
&#xD;
          4. Life expectancy&gt; 12 months;&#xD;
&#xD;
          5. Anatomically suitable for transcatheter aortic valve implantation;&#xD;
&#xD;
          6. Assessed by a multidisciplinary heart team as a patient unsuitable for surgical aortic&#xD;
             valve replacement;&#xD;
&#xD;
          7. Patients who can understand the purpose of the investigation, volunteer to participate&#xD;
             in and sign the informed consent form, and are willing to comply with relevant&#xD;
             examinations and follow-up visits.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          1. Acute myocardial infarction occurred within 30 days before the treatment;&#xD;
&#xD;
          2. Patients with congenital unicuspid aortic valve or aortic root anatomy and lesions&#xD;
             that are not suitable for transcatheter valve implantation;&#xD;
&#xD;
          3. Any therapeutic heart surgery within 30 days;&#xD;
&#xD;
          4. Mixed aortic valve disease(aortic stenosis with severe regurgitation); moderate and&#xD;
             severe mitral stenosis; severe mitral regurgitation; severe tricuspid regurgitation;&#xD;
&#xD;
          5. Blood dyscrasia, including neutropenia (WBC &lt; 3 × 10^9/L), acute anemia(HB &lt;90 g/L),&#xD;
             thrombocytopenia(PLT &lt;50 × 10^9/L), hemorrhagic constitution, and coagulopathy&#xD;
             disease;&#xD;
&#xD;
          6. Untreated coronary artery disease requiring revascularization;&#xD;
&#xD;
          7. Hemodynamic instability requiring systolic support or mechanical heart assistance;&#xD;
&#xD;
          8. Need for emergency surgery for any reason;&#xD;
&#xD;
          9. Obstructive hypertrophic cardiomyopathy;&#xD;
&#xD;
         10. Severe left ventricular dysfunction, left ventricular ejection fraction(LVEF) &lt; 20%;&#xD;
             severe pulmonary hypertension and right ventricular dysfunction;&#xD;
&#xD;
         11. Echocardiography suggests the presence of intracardiac masses, thrombi, or neoplasms;&#xD;
&#xD;
         12. Active peptic ulcer or history of upper gastrointestinal bleeding within 3 months;&#xD;
&#xD;
         13. Allergy to aspirin, heparin, ticlopidine, clopidogrel, nitinol, or contrast agents;&#xD;
&#xD;
         14. Cerebrovascular events including transient ischemic attack(TIA) occurred within 6&#xD;
             months;&#xD;
&#xD;
         15. Renal insufficiency decompensation(end creatinine clearance &lt; 20ml/min), and / or&#xD;
             end-stage renal disease require long-term dialysis treatment;&#xD;
&#xD;
         16. Vascular diseases affecting device access;&#xD;
&#xD;
         17. Active infectious endocarditis or other active infection;&#xD;
&#xD;
         18. Participated in clinical investigations of other drugs or medical devices before the&#xD;
             election, and had not completed the primary endpoint;&#xD;
&#xD;
         19. The investigator judged that the patient had poor compliance and could not complete&#xD;
             the study as required.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>70 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Fuwai Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zhongshan Hospital Fudan University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West China Hospital of Sichuan University</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Second Affiliated Hospital Zhejiang University School of Medicine</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 30, 2020</study_first_submitted>
  <study_first_submitted_qc>November 30, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 7, 2020</study_first_posted>
  <last_update_submitted>November 30, 2020</last_update_submitted>
  <last_update_submitted_qc>November 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aortic Valve Stenosis</mesh_term>
    <mesh_term>Constriction, Pathologic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

